David Sallman, MD, Moffitt Cancer Center, Tampa, FL Recorded on April 9, 2026 David Sallman, MD Associate Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL In this exciting episode, Dr. David Sallman from Moffitt Cancer Center takes a deep dive into acute myeloid leukemia (AML) and the advances transforming patient care. The discussion spans newly approved therapies, including menin inhibitors, as well as promising approaches under investigation in clinical trials, and explores how these innovations are influencing treatment selection, transplantation, and the management of side effects and complications in today’s AML landscape. Tune in today for expert insight into what’s shaping the future of AML care. Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients This episode is supported by Kura Oncology, Inc.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Redefining Normal: Clinical Insights for Healthcare Professionals Supporting Survivors After Treatment
Optimizing Outcomes in Myeloma
Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology
What’s New and What’s Next in CLL
Free AI-powered recaps of Treating Blood Cancers and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.